Thierry Lejemtel, MD
Advanced Heart Failure and Transplant Cardiology · New Orleans, LANPI 1972619757
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $409 of the $506 with a category attached, or 80.8%. 7 manufacturers reported payments, led by Abbott at 48.2% of the total.
Across 16 payments — averaging $31.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$244
- Abiomed$129
- Actelion Pharmaceuticals US, Inc.$62
- Amgen$26
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$18
- Gilead$14
- plus $14 from 1 others
Across 2 payments — averaging $11,646 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$23K
What the payments were for
- Food & beverage$40981%
- Education$9719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $244 |
| Abiomed | 4 | $129 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Amgen | 2 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Gilead | 1 | $14 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$125
How this compares
Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 15 | $18,463 |
| EliquisApixaban | 12 | $9,310 |
| Metoprolol Succinate | 42 | $729 |
| Carvedilol | 25 | $312 |
| ClopidogrelClopidogrel Bisulfate | 16 | $251 |
| Furosemide | 23 | $116 |
| Amlodipine Besylate | 17 | $110 |
| Losartan Potassium | 17 | $110 |
| Spironolactone | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in New Orleans
- Clement EiswirthNew Orleans$277K
- Senthil AnandNew Orleans$51K
- Hector VenturaNew Orleans$39K
- Sapna DesaiNew Orleans$30K
- Selim KrimNew Orleans$9K
- Frank SmartNew Orleans$4K
- Hamang PatelNew Orleans$3K
- Adam LickNew Orleans$2K
- Peter FailHouma$206K
- Shane PrejeanHouma$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.